39719-87-4

Basic information

• Product Name: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide
• Synonyms: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide;N-(5-Methyl-1,3,4-thiadiazole-2-yl)-4-(acetylamino)benzenesulfonamide;N-[4-[[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]sulfonyl]phenyl]acetamide
• CAS NO: 39719-87-4
• Molecular Formula: C₁₁H₁₂N₄O₃S₂
• Molecular Weight: 312.36798
• EINECS: 254-606-7
• Mol File: 39719-87-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.4583 (rough estimate)
• Refractive Index: 1.6270 (estimate)
• Water Solubility: 0.41g/L(37 oC)
• CAS DataBase Reference: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide(39719-87-4)
• EPA Substance Registry System: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide(39719-87-4)

Safety Data

• Hazardous Substances Data: 39719-87-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H12N4O3S2/c1-7(16)12-9-3-5-10(6-4-9)20(17,18)15-11-14-13-8(2)19-11/h3-6H,1-2H3,(H,12,16)(H,14,15)

Upstream product

• 349621-24-5 N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-nitrobenzenesulfonamide 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 144-82-1 sulfamethizole 
• 75-36-5 acetyl chloride 
• 108-33-8 5-methyl-1,3,4-thiadiazol-2-amine 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 

Downstream Products

• 1191951-65-1 N-(4-(N-(5-methyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phenyl)decanamide 
• 144-82-1 sulfamethizole 

Relevant articles and documents

Development of sulfonamide AKT PH domain inhibitors

Disruption of the phosphatidylinositol 3-kinase/AKT signaling pathway can lead to apoptosis in cancer cells. Previously we identified a lead sulfonamide that selectively bound to the pleckstrin homology (PH) domain of AKT and induced apoptosis when present at low micromolar concentrations. To examine the effects of structural modification, a set of sulfonamides related to the lead compound was designed, synthesized, and tested for binding to the expressed PH domain of AKT using a surface plasmon resonance-based competitive binding assay. Cellular activity was determined by means of an assay for pAKT production and a cell killing assay using BxPC-3 cells. The most active compounds in the set are lipophilic and possess an aliphatic chain of the proper length. Results were interpreted with the aid of computational modeling. This paper represents the first structure-activity relationship (SAR) study of a large family of AKT PH domain inhibitors. Information obtained will be used in the design of the next generation of inhibitors of AKT PH domain function.

SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME

Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.